C
AVBP icon

Covestor’s ArriVent BioPharma AVBP Stock Holding History

Covestor’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Sell
9
-1
-10% -$23 ﹤0.01% 2848
2025
Q4 		$0 Sell
10
-1
-9% -$21 ﹤0.01% 2817
2025
Q3 		$0 Buy
11
+7
+175% +$138 ﹤0.01% 2862
2025
Q2 		$0 Hold
4
– – ﹤0.01% 2833
2025
Q1 		$0 Buy
+4
New +$98 ﹤0.01% 2804

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Covestor's AVBP Position: Q1 2026 in Review

Covestor reduced its ArriVent BioPharma (AVBP) stake by 10% in Q1 2026, selling an estimated $23 and leaving 9 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2848.

Covestor first reported a position in AVBP in Q1 2025 and has held it in 5 quarters since. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • Covestor held 9 shares of ArriVent BioPharma worth $0 as of Q1 2026.
  • Covestor sold 1 ArriVent BioPharma share in Q1 2026, an estimated $23.
  • ArriVent BioPharma made up ﹤0.01% of Covestor's portfolio in Q1 2026, its #2848 holding.
  • Covestor first reported a position in ArriVent BioPharma in Q1 2025 and has held it in 5 quarters since.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on Covestor's 13F filing for Q1 2026, filed 5 May 2026.